To estimate whether the lncRNA signature can predict clinical response to mTOR inhibitors, we extracted the data of related drugs from the Genomics of Drug Sensitivity in Cancer (GDSC),28 including four mTOR inhibitors (Rapamycin, AZD8055, NVP‐BEZ235, and Temsirolimus). This evidence concerns the gene MTOR and cancer.